{"schema_version":"secwatch.filing_event.v1","accession":"0001818331-24-000006","form_type":"8-K","ticker":"WGS","cik":"0001818331","company_name":"GeneDx Holdings Corp.","filed_at":"2024-02-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.666556+00:00","generated_at":"2026-06-05T23:18:20.492942+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"GeneDx Q4 revenue $58.1M (+27% YoY); exome/genome revenue up 68%; guides FY2024 $220-230M","bullets":["Q4 revenue from continuing ops $58.1M (+27% YoY); exome/genome revenue $39.2M (+68% YoY).","Adjusted gross margin expanded to 56% (from 41% Q4 2022); exome/genome margin >60%.","Adjusted net loss narrowed to $17.8M, a 76% improvement YoY; cash burn reduced 51% YoY.","FY2024 revenue guidance $220-230M; reiterates path to profitability in 2025.","Exome/genome test volume 15,663 in Q4 (+99% YoY); 49,439 full year."],"urls":{"canonical":"https://secwatch.observer/filing/0001818331-24-000006","json":"https://secwatch.observer/filing/0001818331-24-000006.json","markdown":"https://secwatch.observer/filing/0001818331-24-000006.md","text":"https://secwatch.observer/filing/0001818331-24-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818331/000181833124000006/0001818331-24-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818331/000181833124000006/wgs-20240220.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T23:18:20.492942+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7ced1fdb387e0f3b913827414ed9343f0164ed8f","claim":"GeneDx Holdings Corp. reported the fourth quarter and full year of 2023 results: revenue $58.1 million, net income $17.8 million. Guidance initiated.","evidence_excerpt":"reach profitability in 2025.” Fourth Quarter and Full Year 2023 Financial Results (Unaudited) 1,2,3 Revenues Fourth quarter 2023: • Revenues from continuing operations grew to $58.1 million, an increase of 27% year-over-year and 15% sequentially. ◦ Total company revenues were $57.4 million. • Exome and genome test revenue grew to $39.2 million, an increase of 68%","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818331/000181833124000006/0001818331-24-000006-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year of 2023"},{"label":"Revenue","value":"$58.1 million"},{"label":"Net income","value":"$17.8 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}